Skip to main content

Metastatic Non-small Cell Lung Cancer RELATIVITY1093

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093)

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Kevin B Kim, M.D.
Kevin B Kim, M.D.
Principal investigator
View profile

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Coming Soon

  • Clinical trial

    Adjuvant Non Small Lung Cancer TroFuse-019

    A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Non-Small Cell Lung Cancer A081801

    Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Non-Small Cell Lung Cancer LungMap S1900J

    A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?